Almac - The Manufacture of Peptides for Clinical Trials - 2nd Irish Peptide S...Susan1Beattie
Almac's Steven McIntyre presented in June 2012 at the second Irish Peptide Symposium regarding the manufacture of peptides for clinical trials. See his presentation here.
Presentation by Bernd Blumenberg, president of BASF-YPC Co (BYC), at the Global Petrochemicals 7th Annual Meeting, organised by the World Refining Association (WRA)
Early Phase Pharmacodynamic Models For Respiratory Drug CandidatesSGS
The prevalence of respiratory diseases is increasing worldwide. The most common types are asthma and chronic obstructive pulmonary disease (COPD). Enlarged exposure to certain risk factors and the aging population are responsible for this increase. The large majority of treatments in this therapeutic area consist of inhalation therapy. One of the causes of the rising cost for development of new drugs and the high failure rate is the lack of sensitivity of pharmacodynamics techniques used in translational medicine. In this presentation an overview of current techniques in early development will be given. There will be a special attention for the study of drug disposition in the bronchial tree with techniques like local bronchial pharmacokinetics. Bronchoalveolar lavage may be a promising technique for evaluating drug concentrations and biomarkers in alveolar lining fluid.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
Webinar: New RMC - Your lead_optimization Solution June082017Ann-Marie Roche
The drug discovery landscape is rapidly changing and drives the need to generate leads with lower attrition rates.
In this webinar, our expert Dr. Olivier Barberan discussed how NEW Reaxys Medicinal chemistry in NEW Reaxys allows better discovery and exploration of structure activity relationship and also supports a more efficient property-based drug design approach. He covered the following:
• How has RMC being transformed into a more accessible tool for all users, allowing complex searches and workflows to be easily carried out.
• A demonstration of how more than ever RMC is the only lead-optimization solution you will need.
Almac - The Manufacture of Peptides for Clinical Trials - 2nd Irish Peptide S...Susan1Beattie
Almac's Steven McIntyre presented in June 2012 at the second Irish Peptide Symposium regarding the manufacture of peptides for clinical trials. See his presentation here.
Presentation by Bernd Blumenberg, president of BASF-YPC Co (BYC), at the Global Petrochemicals 7th Annual Meeting, organised by the World Refining Association (WRA)
Early Phase Pharmacodynamic Models For Respiratory Drug CandidatesSGS
The prevalence of respiratory diseases is increasing worldwide. The most common types are asthma and chronic obstructive pulmonary disease (COPD). Enlarged exposure to certain risk factors and the aging population are responsible for this increase. The large majority of treatments in this therapeutic area consist of inhalation therapy. One of the causes of the rising cost for development of new drugs and the high failure rate is the lack of sensitivity of pharmacodynamics techniques used in translational medicine. In this presentation an overview of current techniques in early development will be given. There will be a special attention for the study of drug disposition in the bronchial tree with techniques like local bronchial pharmacokinetics. Bronchoalveolar lavage may be a promising technique for evaluating drug concentrations and biomarkers in alveolar lining fluid.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
Webinar: New RMC - Your lead_optimization Solution June082017Ann-Marie Roche
The drug discovery landscape is rapidly changing and drives the need to generate leads with lower attrition rates.
In this webinar, our expert Dr. Olivier Barberan discussed how NEW Reaxys Medicinal chemistry in NEW Reaxys allows better discovery and exploration of structure activity relationship and also supports a more efficient property-based drug design approach. He covered the following:
• How has RMC being transformed into a more accessible tool for all users, allowing complex searches and workflows to be easily carried out.
• A demonstration of how more than ever RMC is the only lead-optimization solution you will need.
Pharmaceutical Product & Process Design & QualityAjaz Hussain
A reflection on progress made, and challenges to be addressed, in realizing the desired state articulated by the the FDA Initiative on Pharmaceutical Quality for the 21st Century.
In-Vitro-In-Vivo Correlation and ApplicationsRameshwar Dass
Dive into the essence of In-Vitro-In-Vivo Correlation (IVIVC) with our presentation. Uncover the definition, significance, key parameters, methods, and levels, including the innovative realm of in-vitro-in-silico integration
CCK Discussion Forum on Impurity Emergence: A Wake Up Call for Drug Safety & Quality - 13 Oct 2019 at ICCBS, University of Karachi. Session largely participated by qualified and experienced pharmaceutical professionals having diversified educational background and experience.
The compound characterization market is growing increasingly profitable and competitive at the same time. In order to develop a new compound product, the testing step is indispensable. Unlike drug discovery, compound testing is not as restrictive, but understanding the main workflow is still necessary to excel in the market. In order to help you improve both the efficiency and safety of compound testing, we developed the protocol to assist you in your findings.
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...MilliporeSigma
In this webinar, we will discuss:
• The application of RNA therapeutics and the different drug delivery routes used in the clinic.
• Design principles for developing lipids-based RNA formulations.
• Critical parameters to consider for cost effective development and consistent performance of RNA therapeutics and vaccines.
RNA therapeutics are changing the way we address diseases. Applications range from gene therapy, oncology, to vaccines for infectious diseases such as COVID-19.
The performance of RNA therapeutics critically depends on its formulation. Key decisions have to be made early on in the drug development process; choosing the appropriate drug delivery method and novel excipients. Raw material source and judicious choice of chemistry, ultimately determine the quality of novel lipid excipients which, in turn, has a big impact on the performance, reproducibility, costs, and regulatory approval timelines. This webinar will propose solutions to maximize the probability of success while formulating RNA therapeutics and vaccines.
Participate in the interactive webinar now: https://bit.ly/2xXMZlm
Explore our webinar library: www.emdmillipore.com/webinars
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...Merck Life Sciences
In this webinar, we will discuss:
• The application of RNA therapeutics and the different drug delivery routes used in the clinic.
• Design principles for developing lipids-based RNA formulations.
• Critical parameters to consider for cost effective development and consistent performance of RNA therapeutics and vaccines.
RNA therapeutics are changing the way we address diseases. Applications range from gene therapy, oncology, to vaccines for infectious diseases such as COVID-19.
The performance of RNA therapeutics critically depends on its formulation. Key decisions have to be made early on in the drug development process; choosing the appropriate drug delivery method and novel excipients. Raw material source and judicious choice of chemistry, ultimately determine the quality of novel lipid excipients which, in turn, has a big impact on the performance, reproducibility, costs, and regulatory approval timelines. This webinar will propose solutions to maximize the probability of success while formulating RNA therapeutics and vaccines.
Participate in the interactive webinar now: https://bit.ly/2xXMZlm
Explore our webinar library: www.merckmillipore.com/webinars
Pharmaceutical Product & Process Design & QualityAjaz Hussain
A reflection on progress made, and challenges to be addressed, in realizing the desired state articulated by the the FDA Initiative on Pharmaceutical Quality for the 21st Century.
In-Vitro-In-Vivo Correlation and ApplicationsRameshwar Dass
Dive into the essence of In-Vitro-In-Vivo Correlation (IVIVC) with our presentation. Uncover the definition, significance, key parameters, methods, and levels, including the innovative realm of in-vitro-in-silico integration
CCK Discussion Forum on Impurity Emergence: A Wake Up Call for Drug Safety & Quality - 13 Oct 2019 at ICCBS, University of Karachi. Session largely participated by qualified and experienced pharmaceutical professionals having diversified educational background and experience.
The compound characterization market is growing increasingly profitable and competitive at the same time. In order to develop a new compound product, the testing step is indispensable. Unlike drug discovery, compound testing is not as restrictive, but understanding the main workflow is still necessary to excel in the market. In order to help you improve both the efficiency and safety of compound testing, we developed the protocol to assist you in your findings.
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...MilliporeSigma
In this webinar, we will discuss:
• The application of RNA therapeutics and the different drug delivery routes used in the clinic.
• Design principles for developing lipids-based RNA formulations.
• Critical parameters to consider for cost effective development and consistent performance of RNA therapeutics and vaccines.
RNA therapeutics are changing the way we address diseases. Applications range from gene therapy, oncology, to vaccines for infectious diseases such as COVID-19.
The performance of RNA therapeutics critically depends on its formulation. Key decisions have to be made early on in the drug development process; choosing the appropriate drug delivery method and novel excipients. Raw material source and judicious choice of chemistry, ultimately determine the quality of novel lipid excipients which, in turn, has a big impact on the performance, reproducibility, costs, and regulatory approval timelines. This webinar will propose solutions to maximize the probability of success while formulating RNA therapeutics and vaccines.
Participate in the interactive webinar now: https://bit.ly/2xXMZlm
Explore our webinar library: www.emdmillipore.com/webinars
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...Merck Life Sciences
In this webinar, we will discuss:
• The application of RNA therapeutics and the different drug delivery routes used in the clinic.
• Design principles for developing lipids-based RNA formulations.
• Critical parameters to consider for cost effective development and consistent performance of RNA therapeutics and vaccines.
RNA therapeutics are changing the way we address diseases. Applications range from gene therapy, oncology, to vaccines for infectious diseases such as COVID-19.
The performance of RNA therapeutics critically depends on its formulation. Key decisions have to be made early on in the drug development process; choosing the appropriate drug delivery method and novel excipients. Raw material source and judicious choice of chemistry, ultimately determine the quality of novel lipid excipients which, in turn, has a big impact on the performance, reproducibility, costs, and regulatory approval timelines. This webinar will propose solutions to maximize the probability of success while formulating RNA therapeutics and vaccines.
Participate in the interactive webinar now: https://bit.ly/2xXMZlm
Explore our webinar library: www.merckmillipore.com/webinars
Similar to Dr Sally-Ann Cryan, Senior Lecturer in Pharmaceuticals, RCSI (20)
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Dr Sally-Ann Cryan, Senior Lecturer in Pharmaceuticals, RCSI
1. Academic-industrial collaborations in
respiratory drug delivery & development
Dr. Sally-Ann Cryan, School of Pharmacy, RCSI
Gobal BioPharma Summit, Dublin Oct 31st 2012
1
2. Pharmaceutical Development
Drug Compound
(Discovery Phase)
Pharmaceutical
Development
Medicinal product
(patient-end user)
3. Translational pharmaceutics for respiratory therapeutics
• Basic biomedical research
– Molecular pharmaceutics
– In vitro cell culture studies
– HTS for respiratory cells
• Applied clinical research
– Translational pharmaceutics
• formulation of “therapeutic” cargoes
– In vivo pre-clinical studies
• delivery, toxicology, pharmacokinetics
• Industrial research/commercialisation
– Product development
– Device development
– Particle delivery platforms
4. Inhaled medicines
• Ancient civilisations, current smokers
and drug abusers know the efficacy of
inhaled drugs
• Route harnessed by scientists and
physicians for therapeutic drug delivery
• Convenient and targeted drug delivery
directly to site of action for respiratory
conditions
• Growing interest in its use for systemic
delivery and delivery of
biopharmaceuticals
5. Currently inhaled medicines
• Beta-2 agonists e.g. salbutamol, terbutaline
• Corticosteroids e.g. budesonide, beclomethasone
• Anti-cholinergics e.g ipratropium bromide
• Anti-inflammatory e.g. comoglycate
• Mucolytics e.g. DNase, N-acetylcysteine
• Antibiotics e.g. tobramycin, pentamidine
• Anti-proteases e.g. Alpha-1-antitrypsin
– Applications
• Asthma
• COPD
• Cystic fibrosis
6. Respiratory drug delivery market
• Worldwide market for prescription respiratory medicines is now more
than $64B
• Predicted global pulmonary drug delivery technologies market of up to
$44B by 2016
– significant portion of growth supported by technological advances in
biomaterials-based delivery systems
• Eamples of locally acting molecules for inhaled delivery:
– Secretory leukocyte inhibitor (rSLPI), Interferon-γ, Cyclosporin A, Gene
therapies (pDNA, siRNA/shRNA, miRNA)
• Examples of systemically acting molecules for inhaled delivery
– Insulin, FSH, Calcitonin, hGH, Interferon-α, Heparin
7. Challenges from Delivery & Development Perspective
• Pharmaceutical & Regulatory issues
– Inefficient delivery
– Expense of biomolecules
– Instability
– Lack of licensed excipients
• Biopharmaceutical issues
– Inadequate screening tools
– Instability & rapid clearance in vivo
– Multi-drug regimens
– Poor site-specific targeting
– Cell-type specific targeting
– Poor intracellular delivery
– Toxicology and immunogenicity
– Poor IVIVIC
8. Meeting the Challenges & Harnessing Opportunities:
academic-industrial collaboration
Drivers/Needs:
•Therapeutic biomolecules
•Device applications
•Pre-clinical testing
•Personnel training
9. Example 1: Therapeutic Biomolecule
Secretory Leukocyte Protease Inhibitor (rSLPI) therapy
rSLPI therapeutic properties:
• Endogenous cationic protein with antiprotease activity
• Anti-oxidant; Anti-bacterial; Anti-viral activity; Anti-inflammatory
Barriers to inhaled rSLPI therapy:
• Delivery Strategy:
rSLPI-loaded liposomes
– Degradation during aerosolisation & processing Enhance in vivo stability
– Poor lung distribution Improve lung retention &
sustained release
• Pharmacokinetic: short half-life Decrease toxicity
– Proteolytic: degradation by cathepsins Protect during aerosolisation
• Toxicological
Epithelial cells
– High doses may cause lung Irritation
Collaborators: Prof. Gerry McElvaney & Dr. Catherine Greene (Beaumont & RCSI), Prof. Clifford
Taggart (QUB), Amgen
12. Improving rSLPI pharmacokinetics
Intracellular rSLPI
rSLPI Transport in vitro: Calu-3 monolayer
rSLPI transport in vivo: guinea pig asthma model
Gibbons et al., Pharm Res 2011
13. Effect of liposome encapsulation of rSLPI on targeting
DOPC Liposomes DOPS Liposomes Gibbons et al Pharm Res 2011
14. Development of a liposome-rSLPI dry powder for inhalation
Manufacturing an inhalable
powder of DOPS-rSLPI
Gibbons et al
Stability of liquid & dry powder formulations of rSLPI-DOPS
AAPSPharmSciTech 2010
15. Meeting the Challenges & Harnessing Opportunities:
academic-industrial collaboration
Drivers/Needs:
•Therapeutic biomolecules
•Device applications
•Pre-clinical testing
•Personnel training
16. Aerogen™-IDDN collaborations
Projects Focus:
• Project 1 Optimising performance:
Investigation of fluid physicochemical properties on
Aerogen™ performance
• Project 2 Expanding applications:
Effect of nebulisation on the stability of a range of
therapeutic biomolecule
• Project 3 Added value:
Development of convergent device-drug particle
platforms
17. Project 1 Optimising performance
Investigation of fluid physicochemical properties on Aeroneb® performance
18. Project 2 Expanding applications:
Effect of nebulisation on the stability of a range of therapeutic biomolecule
RP-HPLC of calcitonin pre- and post
nebulisation
SEC of calcitonin pre- and post-nebulisation
19. Project 3: Added Value
Nebulised Nanoparticles for
Pulmonary siRNA Delivery
convergent device-nanoparticle
system
Kelly et al 2012 RNAi for
Respiratory disease
20. Development of Nebulised Nanoparticles for
Pulmonary siRNA Delivery
Undifferentiated Calu-3 Differentiated Calu-3
Pre-neb %KD
80
Post-neb %KD
% Knockdown
60
40
20
0
5
1
5
=
1
Pre-neb %KD
/P
=
/P
N
Post-Neb %KD
N
60
G
I
% Knockdown
E
E
P
P
I-
E
P
40
20
0
5
1
5
=
1
/P
=
/P
N
N
G
I
E
E
P
P
I-
E
P
Hibbitts et al unpublished
21. Meeting the Challenges & Harnessing Opportunities:
academic-industrial collaboration
Drivers/Needs:
•Therapeutic biomolecules
•Device applications
•Pre-clinical testing
•Personnel training
22. Example 3: Pre-clinical testing
Screening of Nanomedicines in Respiratory Cells
Oglesby et al. Respiratory Research 2010,
11:148
Collaborators: Prof. Gerry McElvaney & Dr. Catherine Greene (Beaumont & RCSI)
23. Example 3: Pre-clinical testing
B
Screening of Nanomedicines in Respiratory Cells
Control PEI-miRNA, N:P 10:1 Blue=nucleus
Green=cytoskeleton
Red=nanomedicines
Chitosan-miRNA, N:P 50:1 Chitosan-TPP-miRNA, N:P
200:1
25. Advanced tools for Respiratory Drug Development:
3D Modelling of the Airway
Potential Applications:
– Co-culture models
– Toxicity & immunogenciity (including
nanotoxicology)
– Disease models
Taken from Klein et al., Toxicol in Vitro, 2011
– Regeneration
Calu-3 cultures after 14 days
Collagen-Gag Scaffold (O’Brien lab)
Collaborators: RCSI TERG & Dr. Shirley O’Dea & Prof. Noel G McElvaney
26. Opportunities in the Irish Context
• Interdisciplinary research to maximise impact: clinical, biomedical,
pharmaceutical, engineering
• Academic-industrial partnership: convergent technologies
• Biomedical respiratory research
– In vitro and in vivo studies
– Range of therapeutic cargoes emerging
• Small molecules and biomolecules
• Indigenous translational & commercial respiratory research platforms
& know-how
– To realise full clinical & commercial potential of basic research
– Drug product development & IP
– Biomaterials
– Device
– Screening tools
27. Acknowledgements
Research Team: Respiratory Collaborators:
•Dr. Aileen Gibbons •Dr. Marc Devocelle & Dr. James Barlow (RCSI)
•Dr. Awadh Yadav •Prof. NG McElvaney & Dr. Catherine Greene (Beaumont& RCSI)
•Dr. Ciaran Lawlor •Prof. Joe Keane & Dr. Mary O’Sullivan (SJH)
•Dr. Ciara Kelly •Dr. Brian Robertson & Dr. Robert Endres (Imperial College London)
•Dr. Joanne Ramsey •Dr. Shirley O’Dea (NUIM)
•Alan Hibbitts •Prof. Clifford Taggart (QUB)
•Cian O’Leary •Prof. Anthony Hickey (UNC-Chapel Hil)
•Paul McKiernan •Dr Ronan MacLoughlin (Aerogen)
•Prof. Fergal O’Brien (RCSI)